LLY

1,045.35

-1.18%↓

JNJ

205.34

-0.12%↓

ABBV

224.4

-0.21%↓

UNH

324.92

+0.43%↑

AZN

90.2

-0.31%↓

LLY

1,045.35

-1.18%↓

JNJ

205.34

-0.12%↓

ABBV

224.4

-0.21%↓

UNH

324.92

+0.43%↑

AZN

90.2

-0.31%↓

LLY

1,045.35

-1.18%↓

JNJ

205.34

-0.12%↓

ABBV

224.4

-0.21%↓

UNH

324.92

+0.43%↑

AZN

90.2

-0.31%↓

LLY

1,045.35

-1.18%↓

JNJ

205.34

-0.12%↓

ABBV

224.4

-0.21%↓

UNH

324.92

+0.43%↑

AZN

90.2

-0.31%↓

LLY

1,045.35

-1.18%↓

JNJ

205.34

-0.12%↓

ABBV

224.4

-0.21%↓

UNH

324.92

+0.43%↑

AZN

90.2

-0.31%↓

Начало・Списък с акции・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Затворен

1.47 -3.92

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.47

Максимум

1.54

Ключови измерители
By Trading Economics
Приходи	17M -26M
EPS	-0.43
Марж на печалбата	-2,190.837
Служители	171
EBITDA	19M -23M

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	+96.08% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-6M 96M
Предишно отваряне	5.39
Предишно затваряне	1.47

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

1.43 / 1.6 Подкрепа & съпротива

Pliant Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

1.12.2025 г., 21:16 ч. UTC

Придобивния, сливания и поглъщания

Marsh McLennan Agency Acquires Three Hawaii-Based Insurance Brokerages

1.12.2025 г., 18:51 ч. UTC

Значими двигатели на пазара

Shopify Stock Falls on Cyber Monday System Outages

1.12.2025 г., 23:47 ч. UTC

Пазарно говорене

Nikkei May Rise on Bargain Hunting -- Market Talk

1.12.2025 г., 23:27 ч. UTC

Придобивния, сливания и поглъщания

Genting Bhd. Stake in Genting Malaysia Now at 73.13% Vs. 49.36% Ahead of Take Private Offer Made in October

1.12.2025 г., 23:26 ч. UTC

Придобивния, сливания и поглъщания

Genting Bhd.: Offer to Take Genting Malaysia Private Closed on Dec.1

1.12.2025 г., 23:25 ч. UTC

Придобивния, сливания и поглъщания

Bitcoin Rout Picks Up Steam as Investors Fret Over a New 'Crypto Winter' -- WSJ

1.12.2025 г., 21:52 ч. UTC

Придобивния, сливания и поглъщания

Wood Partners Announces Itochu Corp. Purchase of 19.5% of Wood Partners

1.12.2025 г., 21:42 ч. UTC

Придобивния, сливания и поглъщания

Goldman's Latest Acquisition Is a $2 Billion Bet on Active ETFs -- Barrons.com

1.12.2025 г., 21:41 ч. UTC

Пазарно говорене

Canada's GDP Revisions Mean Lower Debt-to-GDP Ratio, Better Productivity -- Market Talk

1.12.2025 г., 21:41 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

1.12.2025 г., 21:41 ч. UTC

Пазарно говорене

Canada's GDP Revisions Mean Lower Debt-to-GDP Ratio, Better Productivity -- Market Talk

1.12.2025 г., 21:17 ч. UTC

Придобивния, сливания и поглъщания

Commercial Metals Expects to Close Foley Products Deal by End of 2025 >CMC

1.12.2025 г., 21:17 ч. UTC

Придобивния, сливания и поглъщания

Commercial Metals Completes Acquisition of Concrete Pipe & Precast for $675M Cash >CMC

1.12.2025 г., 21:15 ч. UTC

Придобивния, сливания и поглъщания

Commercial Metals Completes Acquisition Of Concrete Pipe & Precast, LLC >CMC

1.12.2025 г., 20:15 ч. UTC

Пазарно говорене

Natural Gas Turns Positive Amid Mixed Weather Trends -- Market Talk

1.12.2025 г., 20:00 ч. UTC

Придобивния, сливания и поглъщания

Marsh McLennan Agency Acquires Three Hawai'i-based Insurance Brokerages >MMC

1.12.2025 г., 18:54 ч. UTC

Пазарно говорене

Silver Hits New Record As Momentum Continues -- Market Talk

1.12.2025 г., 18:46 ч. UTC

Пазарно говорене

Luxury Seen With Accelerating Growth Next Year -- Market Talk

1.12.2025 г., 16:41 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

1.12.2025 г., 16:41 ч. UTC

Пазарно говорене

Rapid Wage Growth in Canada to Keep BOC Sidelined -- Market Talk

1.12.2025 г., 16:20 ч. UTC

Пазарно говорене

Yen Could Strengthen Further Against Dollar on Rate-Hike Prospects -- Market Talk

1.12.2025 г., 16:00 ч. UTC

Печалби

Strategy Helped Solve Its Bitcoin-Preferred Problem. Here's How. -- Barrons.com

1.12.2025 г., 15:51 ч. UTC

Придобивния, сливания и поглъщания

Goldman Makes a $2 Billion Bet on 'Boomer Candy' -- WSJ

1.12.2025 г., 15:47 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

1.12.2025 г., 15:47 ч. UTC

Пазарно говорене

Airbus Guidance Is at Risk -- Market Talk

1.12.2025 г., 15:46 ч. UTC

Придобивния, сливания и поглъщания

Synopsys Gets a New Investor. What to Know About Nvidia's Stake. -- Barrons.com

1.12.2025 г., 15:33 ч. UTC

Пазарно говорене

Airbus Selloff May Be Overdone -- Market Talk

1.12.2025 г., 15:26 ч. UTC

Пазарно говорене

Warming Forecast Pressures Natural Gas -- Market Talk

1.12.2025 г., 15:23 ч. UTC

Пазарно говорене

Geopolitical Turmoil Supports Crude Oil -- Market Talk

1.12.2025 г., 14:59 ч. UTC

Придобивния, сливания и поглъщания

Goldman's Latest Acquisition Is a $2 Billion Bet on Active ETFs -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Pliant Therapeutics Inc Прогноза

Ценова цел

By TipRanks

96.08% нагоре

12-месечна прогноза

Среден 3 USD 96.08%

Висок 4 USD

Нисък 2 USD

Според 4 анализатори от Wall Street, предложили 12-месечна ценова цел за Pliant Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

4 ratings

Купи

Задържане

Продай

Според 4 анализатори, дали борсови рейтинги на Pliant Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

1.43 / 1.6Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There is one bearish event.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.